In reply: It is interesting that in the debate on prostate cancer screening, positions are not as far apart as a “debate” implies. I agree with Del Mar and colleagues that all the existing trials have “serious potential methodological flaws” and therefore cannot be taken as evidence that prostate-specific antigen (PSA) screening is effective — nor that it is ineffective. Both sides of the “debate” are consistent with the recent National Health and Medical Research Council conclusion that PSA testing may help some men and may not help others.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.